Somewhat Positive Press Coverage Somewhat Unlikely to Affect Aurinia Pharmaceuticals (AUPH) Share Price

Media stories about Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) have been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Aurinia Pharmaceuticals earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 46.9721225017434 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the news stories that may have impacted Accern Sentiment’s rankings:

Shares of Aurinia Pharmaceuticals (NASDAQ AUPH) opened at $5.77 on Friday. Aurinia Pharmaceuticals has a fifty-two week low of $2.02 and a fifty-two week high of $10.54.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.10. The business had revenue of $0.33 million for the quarter, compared to the consensus estimate of $0.06 million. Aurinia Pharmaceuticals had a negative net margin of 16,648.93% and a negative return on equity of 28.61%. analysts predict that Aurinia Pharmaceuticals will post -1.01 earnings per share for the current fiscal year.

AUPH has been the topic of several analyst reports. BidaskClub lowered shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Vetr lowered shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $6.74 target price on the stock. in a report on Monday, July 31st. Zacks Investment Research raised shares of Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 8th. Cantor Fitzgerald set a $14.00 target price on shares of Aurinia Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, August 11th. Finally, Seaport Global Securities reaffirmed a “buy” rating and issued a $10.00 target price on shares of Aurinia Pharmaceuticals in a report on Friday, October 6th. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $10.79.

ILLEGAL ACTIVITY NOTICE: This report was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.dispatchtribunal.com/2017/11/12/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-aurinia-pharmaceuticals-auph-share-price.html.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Insider Buying and Selling by Quarter for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply